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偶联到不同修饰的纳米粒子上，通过体外药物释放特性、MTT 以及对荷 H22 肿
瘤小鼠的抑制率试验来研究该药物释放体系的性能。 
主要研究结果如下：(1) 利用离子模板法成功制备了粒径可控在 200~500 
nm，性能稳定的壳聚糖纳米粒子。(2) 通过 1-乙基-(3-二甲基氨基丙基)碳二亚胺
(EDC)，FA 可以有效的偶联到纳米粒子上得到 FA 修饰的纳米粒子(FA-NPs)，同
样，通过端甲氧基聚乙二醇琥珀酰亚胺丙酸酯(mPEG-SPA)也可成功的将 PEG 偶
联到纳米粒子上得到 PEG修饰的纳米粒子(PEG-NPs)以及 PEG和 FA共同修饰的
纳米粒子((FA+PEG)-NPs)。激光共聚焦试验证明，FA 能提高 Hela 细胞对粒子的
摄取，而 PEG 则会降低其对粒子的摄取。活体成像试验验证了 FA 可以靶向到肿
瘤部位，而 PEG 可以提高其在血液循环中的时间。(3) 通过对丝裂霉素(MMC)
进行丁二酸改性引入羧基后，在 EDC 的作用下 MMC 能有效的偶联到纳米粒子
上。制备的药物释放体系药物的释放速率呈现突释和缓释双相特征，并且随 pH
的升高而加快。MTT 试验显示，MMC-(FA+PEG)-NPs 在对 Hela 细胞的抑制率高
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Abstract 
Sustained/Controlled release drug delivery system, one of the fast-developing 
technologies over the past two decades in international medical community, by 
changing the dosage form or drug delivery methods, can overcome the shortcomings 
of traditional anti-cancer drugs. Chitosan and its derivatives are very promising 
candidates as sustained/controlled release carrier-materials for a variety of drugs. 
Drugs can be coupled with or encapsulated in the chitosan and its derivatives to 
prepare the anti-tumor drug particulate formulations.  
The main work includes: (1) an ionic gelation combined with chemical 
crosslinking method (namely ion-template method), was developed to prepare 
chitosan nanoparticles (NPs). In the ionic gelation stage, the influences of the mass 
ratio of STPP/chitosan, pH and the molecular weight of chitosan on the particle size 
were investigated. In the chemical crosslink stage, the reaction was monitored by DLS 
and the morphology of NPs was observed by environmental scanning electron 
microscope. (2) Folate (FA) or/and polyethylene glycol (PEG) modified NPs were 
prepared and their functions were tested by laser scanning confocal imaging and in 
vivo optical imaging system respectively. (3) Mitomycin C (MMC), as a model drug, 
was loaded to the different modified NPs. In vitro release study, MTT assays and in 
vivo antitumor effect in hepatoma-22 bearing mice were performed to study the 
behavior of the drug delivery system. 
The main findings are as follows: (1) in the preparation of the NPs, it was found 
that lower pH and lower molecular weight were conducive to the formation of small 
particles. When the chitosan with high molecular weight was used, increasing the 
amount of STPP resulted in bigger size of NPs; but in case of the chitosan with low 
molecular weight, the result turned out contrary to that of chitosan with high 
molecular weight. Overall, this novel method to prepare the chitosan NPs was 
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presence of EDC, folic acid (FA) can be connected to the NPs effectively, similarly, 
the PEG-modified NPs also be successfully prepared by mPEG-SPA. Confocal laser 
imaging proved that FA-NPs could greatly enhance uptake by the Hela cells, but 
PEG-NPs reduced that. In vivo imaging proved that the FA-NPs can be targeted to the 
tumor tissue effectively and the PEGylation prolong its circulatory time. (3) In vitro 
release study show that the drug releases were somewhat biphasic with an initial burst 
release, followed by a subsequent slower release and the release also was highly 
depended on the pH, showing increased release at higher pH values. The MTT assay 
results show that, compared to MMC-NPs, MMC-FA-NPs and MMC-(FA+PEG)-NPs, 
the MMC-(FA+PEG)-NPs had highest cytotoxicity. In vivo antitumor test shown that 
all groups were shown some tumor inhibition, but only the groups administered PEG 
modified nanoparticles and the free MMC yielded a significant tumor inhibition 
compared to the negative control.  
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(Tm = 57°C)，在室温下呈橡胶态，这可能是 PCL 比其它聚酯有更好的药物通透
性的原因。并且具有很好的热稳定性。聚己内酯和己内酯单体都无毒并且生物相
容性良好，在生理环境中可水解，在某些情况下可以酶解。但 PCL 分子中含有
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